CDKN2A and neoplasm: To evaluate the therapeutic efficacy of CD38i, we subcutaneously engrafted the YUMM1.7 mouse melanoma tumor, which carries human-relevant mutations (BrafV600E; Cdkn2a−/−; Pten−/−; Tyrosinase:CreERT2), in B6 mice.